



US 20250257379A1

(19) **United States**(12) **Patent Application Publication**
LEE et al.(10) **Pub. No.: US 2025/0257379 A1**(43) **Pub. Date: Aug. 14, 2025**(54) **NOVEL PHOSPHOENOLPYRUVATE
CARBOXYLASE VARIANT AND METHOD
FOR PRODUCING 5'-INOSINIC ACID USING
SAME**(30) **Foreign Application Priority Data**

Apr. 6, 2023 (KR) 10-2023-0045160

Publication Classification(51) **Int. Cl.**
C12P 19/32 (2006.01)**C12N 9/88** (2006.01)(52) **U.S. Cl.**
CPC **C12P 19/32** (2013.01); **C12N 9/88**
(2013.01); **C12Y 401/01031** (2013.01)(57) **ABSTRACT**

The present invention relates to a novel phosphoenolpyruvate carboxylase variant and a method of producing 5'-inosinic acid using the same. The phosphoenolpyruvate carboxylase variant is obtained by substituting one or more amino acids in the amino acid sequence constituting phosphoenolpyruvate carboxylase to change the activity of the protein, and a recombinant microorganism comprising the phosphoenolpyruvate carboxylase variant is capable of efficiently producing 5'-inosinic acid.

Specification includes a Sequence Listing.(71) Applicant: **DAESANG CORPORATION**, Seoul (KR)(72) Inventors: **Sun Hee LEE**, Seoul (KR); **Tae Yeol CHOI**, Seoul (KR); **Hyun Ho KIM**, Seoul (KR); **Dong Hyun KIM**, Seoul (KR); **Hyun Sook KIM**, Seoul (KR); **Jong Hwan SHIN**, Seoul (KR)(73) Assignee: **DAESANG CORPORATION**, Seoul (KR)(21) Appl. No.: **18/879,948**(22) PCT Filed: **Aug. 31, 2023**(86) PCT No.: **PCT/KR2023/012968**

§ 371 (c)(1),



(2) Date: **Dec. 30, 2024**

Fig. 1



NOVEL PHOSPHOENOLPYRUVATE CARBOXYLASE VARIANT AND METHOD FOR PRODUCING 5'-INOSINIC ACID USING SAME

TECHNICAL FIELD

[0001] The present invention relates to a novel phosphoenolpyruvate carboxylase variant and a method of producing 5'-inosinic acid using the same.

BACKGROUND ART

[0002] 5'-inosinic acid (or inosine monophosphate (IMP)) is an intermediate in the metabolic system of nucleic acid biosynthesis, and not only plays an important physiological role in the bodies of plants and animals, but is also used in various applications, including food, medicine, and various medical applications. In particular, 5'-inosinic acid is a nucleic acid-based seasoning, which has drawn much attention as a savory seasoning, because it has significant synergistic effects on taste when used together with monosodium glutamate (MSG).

[0003] Methods for producing 5'-inosinic acid include a method of enzymatically degrading ribonucleic acid extracted from yeast cells, a method of chemically phosphorylating inosine produced by fermentation, etc. Recently, a method of culturing a 5'-inosinic acid-microorganism and recovering 5'-inosinic acid producing accumulated in the medium has been mainly used.

[0004] For the production of 5'-inosinic acid using microorganisms, in order to improve the efficiency of production of 5'-inosinic acid, there has been development of a variety of recombinant strains or mutant strains having excellent 5'-inosinic acid productivity by applying genetic recombination technology to microorganisms such as *Escherichia coli* and *Corynebacterium*, which are widely used in the production of useful substances such as nucleic acids or L-amino acids, and methods of producing 5'-inosinic acid using the same. In particular, there have been attempts to increase the production of 5'-inosinic acid by targeting genes such as enzymes, transcription factors and transport proteins, which are involved in the biosynthetic pathway of 5'-inosinic acid, or by inducing mutations in promoters that regulate the expression of these genes. However, there are dozens to hundreds of types of proteins such as enzymes, transcription factors and transport proteins, which involved directly or are indirectly in the production of 5'-inosinic acid, and thus much research is still needed on the increase in 5'-inosinic acid productivity by changes in the activity of these proteins.

PRIOR ART DOCUMENTS

Patent Documents

[0005] Korean Patent No. 10-116602

DISCLOSURE

Technical Problem

[0006] An object of present invention is to provide a novel phosphoenolpyruvate carboxylase variant.

[0007] Another object of the present invention is to provide a polynucleotide encoding the variant.

[0008] Still another object of the present invention is to provide a transformant comprising the variant Or polynucleotide.

[0009] Yet another object of the present invention is to provide a method of producing 5'-inosinic acid using the transformant.

Technical Solution

[0010] One aspect of the present invention provides a phosphoenolpyruvate carboxylase variant in which one or more of the amino acids at positions 472 and 673 in the amino acid sequence of SEQ ID NO: 4 is/are substituted with other amino acid(s).

[0011] As used in the present invention, the term “phosphoenolpyruvate carboxylase” catalyzes a reaction of removing carbon dioxide from phosphoenolpyruvate, and it may be a polypeptide or protein consisting of the amino acid sequence of SEQ ID NO: 4 and having phosphoenolpyruvate carboxylase activity.

[0012] Information on the nucleic acid and protein sequences of the phosphoenolpyruvate carboxylase is available from known sequence databases (e.g., GenBank, UniProt).

[0013] According to one embodiment of the present invention, the phosphoenolpyruvate carboxylase may be encoded by the nucleotide sequence of SEQ ID NO: 3.

[0014] The amino acid sequence of the phosphoenolpyruvate carboxylase according to the present invention or the nucleotide sequence encoding the same may include a nucleotide sequence or amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% homology or identity to the amino acid sequence of SEQ ID NO: 4 or the nucleotide sequence of SEQ ID NO: 3. As used herein, the term “homology” or “identity” means the percentage rate of identity between two sequences, which is determined by aligning the reference nucleotide sequence or amino acid sequence and any other nucleotide sequence of amino acid sequence to correspond to each other as much as possible and analyzing the aligned sequences.

[0015] According to one embodiment of the present invention, the phosphoenolpyruvate carboxylase may be derived from wild-type *Corynebacterium stationis*.

[0016] As used in the present invention, the term “variant” refers to a protein that has an amino acid sequence different from the amino acid sequence before mutation by the conservative substitution and/or modification of one or more amino acids at the N-terminus, C-terminus of and/or within the amino acid sequence, which result(s) from mutation in the nucleotide sequence of the gene encoding the protein, but retains the functions or properties of the protein before mutation. As used herein, the term “conservative substitution” means substituting one amino acid with another amino acid having similar structural and/or chemical properties. The conservative substitution may have little or no impact on the activity of the protein or polypeptide. In addition, the term “modification” refers to substitution, insertion, deletion, or the like of one or more amino acids. The amino acid is selected from among alanine (Ala, A), isoleucine (Ile, I), valine (Val, V), leucine (Leu, L), methionine (Met, M), asparagine (Asn, N), cysteine (Cys, C), glutamine (Gln, Q), serine (Ser, S), threonine (Thr, T), phenylalanine (Phe, F), tryptophan (Trp, W), tyrosine (Tyr, Y), aspartic acid (Asp,

D), glutamic acid (Glu, E), arginine (Arg, R), histidine (His, H), lysine (Lys, K), glycine (Gly, G), and proline (Pro, P). **[0017]** In addition, some variants include those in which one or more portions, such as an N-terminal leader sequence of transmembrane domain, have been removed, or those in which a portion has been removed from the N- and/or C-terminus of a mature protein.

[0018] The variant may have increased (enhanced), unchanged, or decreased (weakened) ability compared to that of the protein before mutation. Here, the term “increased or enhanced” includes: a case in which the activity of the protein itself has increased compared to the activity of the protein before mutation; a case in which the overall activity of the protein in the cell is higher than that in the wild-type strain or the strain expressing the protein before mutation due to increased expression or translation of the gene encoding the protein; and a combination thereof. In addition, the term “decreased or weakened” includes: a case in which the activity of the protein itself has decreased compared to the activity of the protein before mutation; a case in which the overall activity of the protein in the cell is lower than that in the wild-type strain or the strain expressing the protein before mutation due to reduced expression or translation of the gene encoding the protein; and a combination thereof. In the present invention, the term “variant” may be used interchangeably with terms such as variant type, modification, variant polypeptide, mutated protein, mutation, and the like.

[0019] According to one embodiment of the present invention, the variant may consist of the amino acid sequence of SEQ ID NO: 2 in which proline at position 472 in the amino acid sequence of SEQ ID NO: 4 is substituted with serine and glycine at position 673 is substituted with aspartic acid.

[0020] More specifically, the phosphoenolpyruvate carboxylase variant may comprise an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% homology or identity to the amino acid sequence of SEQ ID NO: 2.

[0021] Another aspect of the present invention provides a polynucleotide encoding the phosphoenolpyruvate carboxylase variant.

[0022] As used in the present invention, the term “polynucleotide” refers to a DNA or RNA strand having a certain length or more, which is a long-chain polymer of nucleotides formed by linking nucleotide monomers via covalent bonds. More specifically, the term “polynucleotide” refers to a polynucleotide fragment encoding the variant.

[0023] According to one embodiment of the present invention, the polynucleotide may comprise nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2.

[0024] More specifically, the polynucleotide may comprise the nucleotide sequence of SEQ ID NO: 1 in which nucleotide “c” at position 1414 in the nucleotide sequence of SEQ ID NO: 3 encoding phosphoenolpyruvate carboxylase is substituted with nucleotide “t” and nucleotide “g” at position 2018 is substituted with nucleotide “a”.

[0025] Still another aspect of the present invention provides a vector comprising a polynucleotide encoding the phosphoenolpyruvate carboxylase variant.

[0026] Yet another aspect of the present invention provides a transformant comprising the phosphoenolpyruvate carboxylase variant or the polynucleotide.

[0027] As used in the present invention, the term “vector” refers to any type of nucleic acid sequence transfer structure

that is used as a means for transferring and expressing a gene of interest in a host cell. Unless otherwise specified, the term “vector” may mean one allowing the nucleic acid sequence contained therein to be expressed after insertion into the host cell genome and/or one allowing the nucleic acid sequence to be expressed independently. This vector comprises essential regulatory elements operably linked so that an inserted gene can be expressed. As used herein, the term “operably linked” means that a gene of interest and regulatory sequences thereof are functionally linked together in a manner enabling gene expression, and the “regulatory elements” include a promoter for initiating transcription, any operator sequence for regulating transcription, a sequence encoding suitable mRNA ribosome-binding sites, and a sequence for regulating termination of transcription and translation.

[0028] The vector in the present invention is not particularly limited as long as it may replicate in a host cell, and any vector known in the art may be used. Examples of the vector include a natural or recombinant plasmid, cosmid, virus and bacteriophage. Examples of a phage vector or cosmid vector include, but are not limited to, pWE15, M13, λ MBL3, λ MBL4, λ IXII, λ ASHII, λ APII, λ t10, λ t11, Charon4A, and Charon21A, and examples of a plasmid vector include, but are not limited to, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series.

[0029] The vector may typically be constructed as a vector for cloning or as a vector for expression. The vector for expression may be a conventional vector that is used in the art to express a foreign gene or protein in a plant, animal, or microorganism, and may be constructed through various methods known in the art.

[0030] As used in the present invention, the term “recombinant vector” may be transformed into a suitable host cell, and then may replicate regardless of the genome of the host cell or may be integrated into the genome itself. In this case, the “suitable host cell” may contain a replication origin, which is a particular nucleotide sequence which enables the vector to replicate in the suitable host cell and from which replication starts. For example, when the vector used is an expression vector and uses a prokaryotic cell as a host, the vector generally comprises a strong promoter capable of promoting transcription (e.g., pL λ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.), a ribosome binding site for initiation of translation, and a transcription/translation termination sequence. When a eukaryotic cell is used as a host, the vector comprises a replication origin operating in the eukaryotic cell, and examples of the replication origin include, but are not limited to, an f1 replication origin, an SV40 replication origin, a pMB1 replication origin, an adeno replication origin, an AAV replication origin, and a BBV replication origin. In addition, the recombinant vector may comprise a promoter derived from the genome of a mammalian cell (e.g., metallothionein promoter) or a promoter derived from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, HSV-tk promoter, etc.), and generally has polyadenylation sequence transcription termination sequence.

[0031] The recombinant vector may comprise a selection marker. The selection marker serves to select a transformant (host cell) transformed with the vector, and since only cells expressing the selection marker can survive in the medium treated with the selection marker, it is possible to select

transformed cells. Representative examples of the selection marker include, but are not limited to, kanamycin, streptomycin, and chloramphenicol.

[0032] The transformant may be produced by inserting the recombinant vector into a host cell, and the transformant may be obtained by introducing the recombinant vector into an appropriate host cell. The host cell is a cell capable of stably and continuously cloning or expressing the expression vector, and any host cell known in the art may be used.

[0033] Where the vector is transformed into prokaryotic cells to generate recombinant microorganisms, examples of host cells that may be used include, but are not limited to, *E. coli* sp. strains such as *E. coli* DH5 α , *E. coli* JM109, *E. coli* BL21, *E. coli* RR1, *E. coli* LE392, *E. coli* B, *E. coli* X 1776, *E. coli* W3110, and *E. coli* XL1-Blue, *Bacillus* sp. strains such as *Bacillus subtilis* *Bacillus* and *thuringiensis*, *Corynebacterium* sp. strains such as *Corynebacterium glutamicum* and *Corynebacterium stationis*, and various Enterobacteriaceae strains such as *Salmonella typhimurium*, *Serratia marcescens*, and *Pseudomonas* species.

[0034] Where the vector is transformed into eukaryotic cells to generate recombinant microorganisms, examples of host cells that may be used include, but are not limited to, yeast (e.g., *Saccharomyces cerevisiae*), insect cells, plant cells and animal cells, such as Sp2/0, CHO K1, CHO DG44, PER.C6, W138, BHK, COS7, 293, HepG2, Huh7, 3T3, RIN, and MDCK cell lines.

[0035] As used in the present invention, the term “transformation” refers to a phenomenon in which external DNA is introduced into a host cell, thereby artificially causing genetic changes, and the term “transformant” refers to a host cell into which external DNA has been introduced and in which the expression of the gene of interest is stably maintained.

[0036] The transformation may be performed using a suitable vector introduction technique selected depending on the host cell, so that the gene of interest or a recombinant vector comprising the same may be expressed in the host cell. For example, introduction of the vector may be performed by electroporation, heat-shock, calcium phosphate (CaPO₄) precipitation, calcium chloride (CaCl₂) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, lithium acetate-DMSO method, or any combination thereof, without being limited thereto. As long as the transformed gene may be expressed in the host cell, it may be inserted into the chromosome of the host cell, or exist extrachromosomally, without being limited thereto.

[0037] The transformant may include a cell transfected, transformed, or infected with the recombinant vector of the present invention in vivo or in vitro, and may be used in the same sense as a recombinant host cell, a recombinant cell, or a recombinant microorganism.

[0038] Genes inserted into the recombinant vector of the present invention may be introduced into a host cell such as a *Corynebacterium* sp. strain by homologous recombination crossover.

[0039] According to one embodiment of the present invention, the transformant may be a *Corynebacterium* sp. microorganism.

[0040] The *Corynebacterium* sp. microorganism may be, but is not limited to, *Corynebacterium glutamicum*, *Corynebacterium crudilactis*, *Corynebacterium deserti*, *Corynebacterium callunae*, *Corynebacterium suranareae*,

Corynebacterium lubricantis, *Corynebacterium doosanense*, *Corynebacterium efficiens*, *Corynebacterium uterequi*, *Corynebacterium stationis*, *Corynebacterium pac-aense*, *Corynebacterium singulare*, *Corynebacterium humireducens*, *Corynebacterium marinum*, *Corynebacterium halotolerans*, *Corynebacterium spheniscorum*, *Corynebacterium freiburgense*, *Corynebacterium striatum*, *Corynebacterium canis*, *Corynebacterium ammoniagenes*, *Corynebacterium renale*, *Corynebacterium pollutisoli*, *Corynebacterium imitans*, *Corynebacterium caspium*, *Corynebacterium testudinoris*, *Corynebacterium pseudopelargi*, or *Corynebacterium flavesens*.

[0041] The transformant in the present invention may be a strain either comprising the above-described phosphoenolpyruvate carboxylase variant or a polynucleotide encoding the same or comprising the vector comprising the same, a strain expressing the phosphoenolpyruvate carboxylase variant or the polynucleotide, or a strain having activity for the phosphoenolpyruvate carboxylase variant, without being limited thereto.

[0042] The transformant of the present invention may comprise other protein variants or genetic mutations, in addition to the phosphoenolpyruvate carboxylase variant.

[0043] According to one embodiment of the present invention, the transformant may have the ability to produce 5'-inosinic acid.

[0044] The 5'-inosinic acid is a nucleic acid-based compound that gives flavor to food, especially umami (savory) taste, and is used with the same meaning as inosine monophosphate (IMP).

[0045] The transformant may naturally have the ability to produce 5'-inosinic acid or may be one artificially endowed with the ability to produce 5'-inosinic acid.

[0046] According to one embodiment of the present invention, the transformant may have an increased ability to produce 5'-inosinic acid, due to a change in phosphoenolpyruvate carboxylase activity.

[0047] As used in the present invention, the term “increased ability to produce” means that 5'-inosinic acid productivity has increased compared to that of the parent strain. As used herein, the term “parent strain” refers to a wild-type strain or mutant strain to be mutated, and includes a strain that is to be mutated directly or to be transformed with a recombinant vector or the like. In the present invention, the parent strain may be a wild-type *Corynebacterium* sp. strain or a *Corynebacterium* sp. strain mutated from the wild-type microorganism.

[0048] The transformant according to the present invention exhibits an increased ability to produce 5'-inosinic acid compared to the parent strain, due to the change in phosphoenolpyruvate carboxylase activity caused by introduction of the phosphoenolpyruvate carboxylase variant thereinto. More specifically, the amount of 5'-inosinic acid produced by the transformant may be at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than that produced by the parent strain, or may be 1.1-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, or 10-fold higher than that produced by the parent strain, without being limited thereto. For example, the amount of 5'-inosinic acid produced by the transformant comprising the phosphoenolpyruvate carboxy-

lase variant may be at least 5%, specifically 5 to 50% (preferably 10 to 40%) higher than that produced by the parent strain.

[0049] Still yet another aspect of the present invention provides a method for producing 5'-inosinic acid, comprising steps of: culturing the transformant in a medium; and recovering 5'-inosinic acid from the transformant or the medium in which the transformant has been cultured.

[0050] The culturing may be performed using a suitable medium and culture conditions known in the art, and any person skilled in the art may easily adjust and use the medium and the culture conditions. Specifically, the medium may be a liquid medium, without being limited thereto. Examples of the culturing method include, but are not limited to, batch culture, continuous culture, fed-batch culture, or a combination thereof.

[0051] According to one embodiment of the present invention, the medium should meet the requirements of a specific strain in a proper manner, and may be appropriately modified by a person skilled in the art. For culture media for *Escherichia* sp. strains, reference may be made to, but (Manual of Methods for not limited to, a known document General Bacteriology, American Society for Bacteriology, Washington D.C., USA, 1981).

[0052] According to one embodiment of the present invention, the medium may contain various carbon sources, nitrogen sources, and trace element components. Examples of carbon sources that may be used include: sugars and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch, and cellulose; oils and fats such as soybean oil, sunflower oil, castor oil, and coconut oil; fatty acids such as palmitic acid, stearic acid, and linoleic acid; alcohols such as glycerol and ethanol; and organic acids such as acetic acid. These substances may be used individually or as a mixture, without being limited thereto. Examples of nitrogen sources that may be used include peptone, yeast extract, meat extract, malt extract, Corn steep liquor, soybean meal, urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, and ammonium nitrate. The nitrogen sources may also be used individually or as a mixture, without being limited thereto. Examples of phosphorus sources that may be used include, but are not limited to, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts. In addition, the culture medium may contain, but is not limited to, metal salts such as magnesium sulfate or iron sulfate, which are required for growth. In addition, the culture medium may contain essential growth substances such as amino acids and vitamins. Moreover, suitable precursors may be used in the culture medium. The medium or individual components may be added to the culture medium batchwise or in a continuous manner by a suitable method during culturing, without being limited thereto.

[0053] According to one embodiment of the present invention, the pH of the culture medium may be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid to the microorganism culture medium in an appropriate manner during the culturing. In addition, during the culturing, foaming may be suppressed using an anti-foaming agent such as a fatty acid polyglycol ester. Additionally, to keep the culture medium in an aerobic condition, oxygen or an oxygen-containing gas (for example, air) may be injected

into the culture medium. The temperature of the culture medium may be generally 20° C. to 45° C., for example, 25° C. to 40° C. The culturing may be continued until a desired amount of a useful substance is produced. For example, the culturing time may be 10 hours to 160 hours.

[0054] According to one embodiment of the present invention, in the step of recovering 5'-inosinic acid from the cultured transformant the medium in which the transformant has been cultured, the produced 5'-inosinic acid may be collected or recovered from the medium using a suitable method known in the art depending on the culture method. Examples of a method that may be used to recover the produced 5'-inosinic acid include, but are not limited to, centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, fractional dissolution (e.g., ammonium sulfate precipitation), chromatography (e.g., ion exchange, affinity, hydrophobicity and size exclusion), and the like.

[0055] According to one embodiment of the present invention, the step of recovering 5'-inosinic acid may be performed by centrifuging the culture medium at a low speed to remove biomass and separating the obtained supernatant through ion-exchange chromatography.

[0056] According to one embodiment of the present invention, the step of recovering 5'-inosinic acid may include a process of purifying the 5'-inosinic acid.

Advantageous Effects

[0057] The phosphoenolpyruvate carboxylase variant according to the present invention is obtained by substituting one or more amino acids in the amino acid sequence constituting phosphoenolpyruvate carboxylase to change the activity of the protein, and a recombinant microorganism comprising the phosphoenolpyruvate carboxylase variant is capable of efficiently producing 5'-inosinic acid.

BRIEF DESCRIPTION OF DRAWINGS

[0058] FIG. 1 shows the structure of a pk19msb plasmid according to one embodiment of the present invention.

MODE FOR INVENTION

[0059] Hereinafter, the present invention will be described in more detail. However, this description is merely presented by way of example to facilitate the understanding of the present invention, and the scope of the present invention is not limited by this exemplary description.

Example 1. Construction of Strain Expressing Phosphoenolpyruvate Carboxylase Variant

[0060] To evaluate the effect of a variant (SEQ ID NO: 2) having a substitution of serine(S) for proline (P) at position 472 and a substitution of aspartic acid (D) for glycine (G) at position 673 in the amino acid sequence of phosphoenolpyruvate carboxylase (SEQ 4) on the production of 5'-inosinic acid, the present inventors constructed a vector for expressing the phosphoenolpyruvate carboxylase variant and a strain into which the vector has been introduced.

1-1. Construction of Vector for Expression of Phosphoenolpyruvate Carboxylase Variant

[0061] Using the genomic DNA of wild-type *Corynebacterium stationis* ATCC6872 as a template, PCR was per-

formed using a primer pair of primers 1 and 2. The PCR fragment and a pK19msb plasmid (SEQ ID NO: 5) were treated with the restriction enzyme *smal* (NEB) and ligated together using T4 ligase. The resulting plasmid was named pK_PC.

[0062] The PCR amplification was performed using Pfu PreMix (Bioneer) under the following conditions: denaturation at 95° C. for 5 min, and then 30 cycles, each consisting of 95° C. for 30 sec, 58° C. for 30 sec, and 72° C. for 1 min and 30 sec, followed by reaction at 72° C. for 5 min.

[0063] The primer sequences used for plasmid construction are shown in Table 1 below,

TABLE 1

Primer name	SEQ ID NO.	Primer sequence (5'-3')
Primer 1	6	CTCTGCTCGCTCACTGGTCT
Primer 2	7	TACTCGCTGTGTCGTAGCGGG

1-2. Construction of Mutant Strain into Which Phosphoenolpyruvate Carboxylase Variant Has Been Introduced

[0064] An electrocompetent cell preparation method, a modification of the method of van der Rest et al., was used as a method for transformation of *Corynebacterium stationis* KCCM13339P.

[0065] First, *Corynebacterium stationis* KCCM13339P was primarily cultured in 10 mL of 2YT medium (containing 16 g/l of tryptone, 10 g/l of yeast extract, and 5 g/l of sodium chloride) supplemented with 2% glucose, thus preparing a seed culture. Isonicotinic acid hydrazine at a concentration of 1 mg/ml and 2.5% glycine were added to 100 ml of 2YT medium free of glucose. Next, the seed culture was inoculated into the 2YT medium to reach an OD₆₁₀ value of 0.3, and then cultured at 30° C. and 180 rpm for 5 to 8 hours so that the OD₆₁₀ value reached 0.6 to 0.7. The culture was kept on ice for 30 minutes, and then centrifuged at 3,500 rpm at 4° C. for 10 minutes. Thereafter, the supernatant was discarded and the precipitated *Corynebacterium stationis* KCCM13339P was washed 4 times with a 10% glycerol solution and finally re-suspended in 0.5 ml of a 10% glycerol solution, thereby preparing competent cells. Electroporation was performed using a Bio-Rad electroporator. The prepared competent cells and the constructed pK_PC vector were placed in an electroporation cuvette (0.2 mm), and then subjected to electroporation under conditions of 2.5 kV, 200Ω and 12.5 μF. Immediately after completion of the electroporation, 1 ml of regeneration (RG) medium (containing 18.5 g/l brain heart infusion and 0.5 M sorbitol) was added to the cells which were then heat-treated at 46° C. for 6 minutes. Next, the cells were cooled at room temperature, transferred into a 15-ml cap tube, incubated at 30° C. for 2 hours, and plated on a selection medium (containing 5 g/l tryptone, 5 g/l NaCl, 2.5 g/l yeast extract, 18.5 g/l brain heart infusion powder, 15 g/l agar, 91 g/l sorbitol, and 20 μg/l kanamycin). The cells were cultured at 30° C. for 72 hours, and the generated colonies were cultured in medium until the stationary phase to induce secondary recombination. Then, the cells were diluted to 10⁻⁵ to 10⁻⁷, and plated on an antibiotic-free plate medium (containing 10% sucrose),

and a strain having no kanamycin resistance and grown on the medium containing 10% sucrose was selected and named IPC-1.

Experimental Example 1. Evaluation of 5'-Inosinic Acid Productivity of Strain Expressing Phosphoenolpyruvate Carboxylase Variant

[0066] 5'-Inosinic acid productivity was compared between the parent strain KCCM13339P and the mutant strain IPC-1 into which the phosphoenolpyruvate carboxylase variant has been introduced.

[0067] Each strain (parent strain or mutant strain) was inoculated at 1% by volume into a 100-mL flask containing 10 mL of the medium for 5'-inosinic acid production shown in Table 2 below, and cultured with shaking at 200 rpm at 34° C. for 45 hours. After completion of the culturing, the concentration of 5'-inosinic acid in the medium was measured using HPLC (Agilent), and the results are shown in Table 3 below.

TABLE 2

Component	Content
Glucose	70 g/L
(NH ₄) ₂ SO ₄	2 g/L
MgSO ₄	1 g/L
Urea	2 g/L
Yeast extract	20 g/L
KH ₂ PO ₄	2 g/L
FeSO ₄	10 mg/L
MnSO ₄	10 mg/L
Thiamine_HCl	5 mg/L
biotin	20 μg/L
Cystein	20 mg/L
Bata-alanine	20 mg/L
Adenine	30 mg/L

TABLE 3

Strain	5'-inosinic acid production (g/L)
KCCM13339P	20.0
IPC-1	23.2

[0068] As shown in Table 3 above, it was confirmed that the amount of 5'-inosinic acid produced by the mutant strain into which the phosphoenolpyruvate carboxylase variant has been introduced was increased by about 16% compared to that produced by the parent strain, due to substitution of the amino acids at positions 472 and 673 with other amino acids. These results suggest that introduction of point mutations into phosphoenolpyruvate carboxylase provides a significant effect on 5'-inosinic acid productivity.

[0069] So far, the present invention has been described with reference to the preferred embodiments. Those of ordinary skill in the art to which the present invention pertains will appreciate that the present invention may be embodied modified in forms without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative point of view, not from a restrictive point of view. The scope of the present invention is defined by the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.

[Accession Number]

[0070] Depository Authority: Korean Culture Center of
Microorganisms (KCCM)

[0071] Accession Number: KCCM13339P

[0072] Deposit Date: Mar. 29, 2023

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

To: DAESANG


178 Magokjungang-ro,

Gangseo-gu,

Seoul, 07789,

Republic of Korea

RECEIPT IN THE CASE OF AN ORIGINAL
DEPOSIT issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Corynebacterium stationis</i> MW 5520	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCCM13339P
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on April. 01. 1993 (date of the original deposit). ¹ (KFCC-11786)	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on April. 01. 1993 (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on March. 29. 2023 (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Culture Center of Microorganisms Address: Yurim B/D 45, Hongjeonae-2ga-gil Seodaemun-gu SEOUL 03461 Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: June 29, 2022.

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

Form BP/4 (sole page)

The above translation proves that there is no difference from the content of the original text.

August 31, 2023

Patent Attorney Hyuk Park



SEQUENCE LISTING

Sequence total quantity: 7

SEQ ID NO: 1 moltype = DNA length = 2805
 FEATURE Location/Qualifiers
 source 1..2805
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 1

```

atgttcaata cgaactgacgt ttcgctggaa aggaacccca ctgcaatgag tgaacagggtg 60
cgcgatgata tccgactgct aggacgcac ctcggccgag taattgccga gcaagaaggc 120
gaagatgtat ttgagttggg ggaagcact cgcgcgttgg ccttcggggg ggcgcgcggt 180
gaggaaaaag ctgaggcttt gctggcgacc ttccggacta tcgatgaaa cgcacatcaac 240
ctcgttgccg gttctttcag ccactttgcg ctgatggcga atatcgaga ggacctcgac 300
gatgaaacgg cgcttgacgc ccgcgaggat gctggtgcac aggcctccga tgcctccctg 360
cacggagttt tgggcaagct caaggcggcg aaagacatca aaacaagtga tgtcaccctg 420
atcttgatg cgcgcgaagt ctccctggtt ttaccgcac accccacgga gacacggcgt 480
cgtacggtat ttgatgtcca ggagcgcatc tgggcgctat tgcgtgagcg ccacagcatc 540
ttggcccaac cgcaaacagc aaggcttgaa gcccgctctg ctgagattga acgcgaggct 600
cacctgcgca tgaccatcct gtggcaaac gcgttaattc gcattgcac gccacagatc 660
gaagatgaag taaacgtagg tctgcgctac ttcaagcgca gcctcttaga gcaggtagcg 720
gcgattaaac tgcgacaccat cgcgggctt cgcgatgtct tcggcgcatc agtgcccaac 780
cggcaagttg tgcgcacagg gtcattggatc ggccggcgacc acgatggcaa tccttatgtc 840
accggcgata ctttgaccta cgcgacgcca caggcccgcg ataccatcct ggaatactac 900
gttgatgagc tcgcagcact agaaaaggaa ctgagcttat cagaccgcta ttcagaaagt 960
tccgcggaat tacaagaact ggccacgcgc gggagaaacg atattccaag tcgcgtcgat 1020
gagccttacc gcagggcaat ccacggagtg caggacgcca tgatagctac ccgcgcagcc 1080
gttgaggag aagccgcagc tgagtctggg gaattttcac cttatgcctc cccgaccacg 1140
tttcgcacgg atttgagggt tattgaccgg tctttgcggc aatttaatga tgcgatcatc 1200
gccgacgata ggtctgctgc aattctttct gccgtggata cttttggctt ccacctcaat 1260
gctttggatc tgcgtcagaa ctcggagctc ttccaggccg tcttggaaga acttttcgct 1320
gccgcggggc ttactgcacc agatgccgga tacgccagcc tggatgagag cgcgaagcgt 1380
gaactactag tagctgagct cacctctgct cgtcactggt tcttcccggt gtctcaagac 1440
ttcagtgca acacgggaag cgaactaggg atcttccggg cagcagccca gccgctcgag 1500
ttactggggc caggtgttgt ccacactgct attgtttcaa tgaccggtac agtcagcgat 1560
attttgaac cgatggtact gctcaaagaa gttaggcatca taagctttaa cccagcccag 1620
caacgcctcg ttggttcagt ggacatcgca ccgctttttg aaaccattga agacttaaa 1680
gctggcgccg agatccttca agaactatgg gaagttgacc tttaccggcg atacttgccg 1740
gggcgcgaag acgtccaaga agtcgtgttg ggggtattccg actccaataa agacggcggg 1800
tatttgtctg cgaattgggc ttatatgat cgcgagctag ccacgtcaa gcccttcgat 1860
acgcacggca tcgggttgcc cttttcacat ggccgcggcg gtgctgtggg tcgcggtggc 1920
gggcgcagct acgatgccat cttggcccag cccgaagggt cggctccggg cagcgtgcgt 1980
attaccgagc aaggtgaggt catctctgcc cgtacgaca cagcgagtag cgcgcgccgc 2040
cacctggaag cttttgtcgc gggcacgcta gaagcctctc tactggatag tgaagagcta 2100
aaagagcctg aacgcgccta tggcatcatg cgggatatcg cctcgtggc cggtgagaaa 2160
tatcgcaaat tgggtgcgca tgactccggg ttatcgact acttcacgca atccacgcca 2220
ttgcacgaaa ttggcgacct caatatggga tcacgtccaa ctgctcgcaa gcagacgga 2280
tccatcggtg acttgccgcg gattccatgg gtctctgcat ggtcgcagtc gcgcgttaac 2340
ctgcgcggct cgttcggagc ggccacaggc atcatgcgct gggctggcga agacagagac 2400
cgctggcaag atttgcccaa gctttatcag gcattggcgt tctttcgttc cgtgctcgac 2460
aacatggcgc aggtcatggg gaaagcgtcg atgaatctcg caaagatcta ctccacgctt 2520
tcgatgacc ccacggtctc ccagcgcgtg tttaacacca tctgggacga atacgaatta 2580
accaaagaag tattcttcgc catcactggt catgattcgc tcatggctgg taatgagcgt 2640
ttggagcgtt cagtacagcg acgctatcca tacttactgc cgctcaacgc catccagatt 2700
gagttgctgc gcgcgtaccg tcggggcgag gatacattct tggctcttaa gaccatccag 2760
gtgacctga acggacttgc gacaggacta cgcacctcag gctag 2805

```

SEQ ID NO: 2 moltype = AA length = 934
 FEATURE Location/Qualifiers
 source 1..934
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 2

```

MFNSTDVSLE NRPTAMSEQV RDDIRLLGRI LGRVIAEQEG EDVFELVEST RRLAFGVARG 60
EEKAEALLAT FRTIDENRIN LVARSFSHFA LMANIAEDLD DETALAAED AGAQAPDASL 120
HGVLGKLLKAA KDIKTSVTR ILDAAQVSPV FTAHPTETRR RTVFDVQERI VALLRERHSI 180
LAQQTARLE ARLAEIEREA HLRMTILWQT ALIRIARPOI EDEVNGLRY FKRSLEQVP 240
AINRDTIAGL RDVFGASVPN RQVVRTGSI GGDHGNPYV TGDTLTYATR QAADTILEY 300
VDELALEKE LSLSDRYSES SAEQLQELAT GRNDIPSVD EPYRRAIHGV HGRMIATRA 360
VAGEAAAESG EFSFYASPTQ FRTDLQVIDR SLRQFNDAII ADDRLLRILS AVDTFGFHLN 420
ALDLRQNSSE FEAVLDELFA AAGVTAPDAG YASLDESAGR ELLVAELTSA RSLVFPWSQD 480
FSADTERELG IFRAAAQAVE LLGPGVPHC IVSMGTGTVSD ILEPMVLLKE VGIISFNPAQ 540
QRLVGSVDIA PLFETIEDLK AGAEILQELW EVDLYRGYLR GREVDQEVVL GYSDSNKDG 600
YLSANWALYD AQLAIVKACD THGIGLRFSH GRGGAVGRGG GPTYDAILAQ PEGAVRGSVR 660
ITEQGEVISA RYDTASTARR HLEAFVAGTL EASLLDTEKL KEPERAYGIM RDIASLAGEK 720
YAQLVRDDSG FIDYFTQSTP LHEIGDLNMG SRPTARKQTE SIGDLRAIPW VLWSQSRVN 780
LPGWFGVGTG IMRWAGEDET RWQDLRKLYQ AWPFFRSVLD NMAQVMGKAS MNLAKIYSTL 840

```

-continued

VDDPTVSQVR	FNTILDEYEL	TKEVFFRITG	HDSL MAGNER	LEERSVQRRYP	YLLPLNAIQI	900
ELLRRYRAGE	DTFLVSKTIQ	VTMNGLATGL	RTSG			934

SEQ ID NO: 3 moltype = DNA length = 2805
 FEATURE Location/Qualifiers
 source 1..2805
 mol_type = genomic DNA
 organism = Corynebacterium stationis

SEQUENCE: 3

atgttcaata	gcaactgacgt	ttcgctggaa	aggaacccca	ctgcaatgag	tgaacaggtg	60
cgcgatgata	tccgactgct	aggacgcac	ctcgcccgag	taattgcgga	gcaagaaggc	120
gaagatgtat	ttgagttggt	ggaaagcact	cgccgcttgg	ccttcggggg	ggcgcgcggt	180
gaggaaaaaa	ctgaggcttt	gctggcgacc	ttccggacta	tcgatgaaaa	ccgcatacaac	240
ctcgttgcgc	gttctttcag	ccactttgcy	ctgatggcga	atatcgaga	ggacctcgac	300
gatgaaacgg	cgcttgacgc	ccgcgaggat	gctggtgcac	aggctcccca	tgcttccctg	360
cacggagttt	tgggcaagct	caaggcggcg	aaagacatca	aaacaagtga	tgtcaccctg	420
atcttggatg	ccgcgcaagt	ctccctgtt	tttacgcac	accccacgga	gacacggcgt	480
cgtacggtat	ttgatgtcca	ggagcgcatc	gtggcgctat	tgcgtgagcg	ccacagcatc	540
ttggcccaac	gcgaacacgc	aaggcttgaa	gcccgcttgg	ctgagattga	acgcgaggct	600
caactgcgca	tgaccatcct	gtggcaaac	gcgttaattc	gcattgcacg	gccacagatc	660
gaagatgaag	taaacgtagg	tctgcgctac	ttcaagcgca	gcctcttaga	gcaggtaaccg	720
gcgattaaac	gcgacaccat	cgcgggctt	cgcgatgtct	tcggcgcatc	agtgcaccaac	780
cggcaagtgt	tgcgcacagg	gtcatggatc	ggcgccgacc	acgatggcaa	tccttatgtc	840
acccgcgata	ctttgacccta	cgcgacgcga	caggcccgcg	ataccatcct	ggaatactac	900
gttgatgagc	tcgcagcact	agaaaaggaa	ctgagcttat	cagaccgcta	ttcagaaagt	960
tcgcgggaat	tacaagaact	ggccacgcgc	gggagaaaacg	atattccaag	tcgcgtcgat	1020
gagccttacc	gcagggcaat	ccacggagtg	cacggacgca	tgatagctac	ccgcgcagcc	1080
gttgacagg	aagccgcagc	tgagtctggg	gaattttcac	cttatgcctc	cccgaaccag	1140
tttcgcacgg	atttgacagg	tattgacccg	tctttgcggc	aatttaatga	tcgcagatc	1200
gccgacgata	ggctgctgcy	aattctttct	gccgtggata	cttttggtct	ccacctcaat	1260
gctttggatc	tgcgtcagaa	ctcggagctc	ttcgaggccg	tcttggacga	acttttcgct	1320
gccgcggggc	ttactgcacc	agatgcggga	tacgccagcc	tggatgagag	cgccaagcgt	1380
gaactactag	tagctgagct	cacctctgct	cgcccaactg	tcttcccggt	gtctcaagac	1440
ttcagtgcaag	acacggaaacg	gaactaggg	atcttccggg	cagcagccca	ggcgtcgag	1500
ttactggggc	caggtgttgt	cccacactgc	attgtttcaa	tgaccggtac	agtcagcgat	1560
attttggaac	cgatgggtact	gctcaaagaa	gtaggcatca	taagctttaa	cccagcccag	1620
caacgcctcg	ttggttcagt	ggacatcgca	ccgctttttg	aaaccattga	agacttaaa	1680
gctggcgcg	agatccttca	agaactatgg	gaagttgacc	tttaccgcgg	atacttgccg	1740
gggcgcgaag	acgtccaaga	agtcgtgttg	gggtattccg	actccaataa	agacggcggg	1800
tattgtctcg	tgaattgggc	tttatatgat	gcgcagctag	ccatcgctca	ggcctcgcat	1860
acgcacggca	cggggttgcc	cttttcacat	ggccgcggcg	gtgctgtggg	tcgcggtggc	1920
gggcgcagct	acgatgccat	cttgcccag	cccgaaggtg	cggtccgggg	cagcgtgcgt	1980
attaccgagc	aaggtgaggt	catctctgcc	cgctacggca	cagcaggtac	cgcgcgcgcg	2040
caactggaag	cttttgctgc	gggcacgcta	gaagcctctc	tactggatc	tgaaaagcta	2100
aaagagcctg	aacgcgccta	tgccatcatg	cgggatcatg	cctcgctggc	cggtgagaaa	2160
tatgcgcaat	tggtgcgcga	tgactccggg	tttatcgact	acttcacgca	atccacgcca	2220
ttgcacgaaa	ttggcgacct	caatatggga	tcacgtccaa	ctgctcgcaa	gcagaccgaa	2280
tcacatcggt	acttgccgcg	gattccatgg	gtcctgtcat	ggtcgagtc	ggcgcttaac	2340
ctgcgcggct	gggtcggaat	gggcacaggc	atcatgcgct	gggttgccga	agacgagacc	2400
cgtcggaag	atttgccgaa	gctttatcag	gcattggcgt	tccttcgttc	cgtgctcgac	2460
aacatggcgc	aggtcatggg	gaaagcgtcg	atgaatctcg	caaagatcta	ctccacgctt	2520
gtcgatgacc	ccacggtctc	ccagcgcgtg	tttaacacca	tcctggacga	atacgaatta	2580
accaaagaag	tattcttcgc	catcactggt	catgattcgc	tcattggctg	taatgagcgt	2640
ttggagcgtt	cagtacagcg	acgctatcca	tacttactgc	cgctcaacgc	catccagatt	2700
gagttgctgc	gccgctaccg	tcggggcgag	gatacattct	tggtctctaa	gaccatccag	2760
gtgaccatga	acggacttgc	gacaggacta	cgcacctcag	gctag		2805

SEQ ID NO: 4 moltype = AA length = 934
 FEATURE Location/Qualifiers
 source 1..934
 mol_type = protein
 organism = Corynebacterium stationis

SEQUENCE: 4

MFNSTDVSL	RNPMTAMSEV	RDDIRLLGRI	LGRVIAEQEG	EDVFELVEST	RRLAFGVARG	60
EKAEALLAT	FRTIDENRIN	LVARFSFHPA	LMANIAEDLD	DETALAARED	AGAQAAPDASL	120
HGVLGKLKAA	KDIKTSVTR	ILDAAQVSPV	FTAHPETERR	RTVFDVQERI	VALLRERHSI	180
LAQPQTARLE	ARLAIEIEREA	HLRMTILWQT	ALIRIARPQI	EDEVNVGLRY	FKRSLLLEQVP	240
AINRDTIAGL	RDVFGASVPN	RQVVRTGSWI	GGDHGDNPYV	TGDTLTATYR	QAADTILEYY	300
VDELAALKE	LSLSDRYSES	SAELQELATR	GRNDIPSRVD	EPYRRRAIHG	HGRMIATRAA	360
VAGEAAASG	EFSPYASPTQ	FRTDLQVIDR	SLRQFNDAII	ADDRLLRILS	AVDTFGFHLN	420
ALDLRQNS	FEAVLDELFA	AGVVTAPDAG	YASLDESAKR	ELLVAELTSA	RPLVFPWSQD	480
FSADTERELG	IFRAAAQAVE	LLGPGVVPNC	IVSMTGTVSD	ILEPMVLLKE	VGIISFNPAQ	540
QRLVGSVDIA	PLFETIEDLK	AGAEILQELW	EVDLYRGYLR	GREDEVQEVV	GYSDSNKDG	600
YLSANWALYD	AQLAIVKACD	THGIGLRFSH	GRGGAVERGG	GPTYDAILAQ	PEGAVRGSVR	660
ITEQGEVISA	RYGTASTARR	HLEAFVAGTL	EASLLDTEKL	KEPERAYGIM	RDIASLAGEK	720
YAQLVRDDSG	FIDYFTQSTP	LHEIGDLNMG	SRPTARKQTE	SIGDLRAIPW	VLSWSQSRVN	780

-continued

LPGWFGVGTG	IMRWAGEDET	RWQDLRLKLYQ	AWPFFRSVLD	NMAQVMGKAS	MNLAKIYSTL	840
VDDPTVSQRV	FNTILDEYEL	TKEVFFRITG	HDSL MAGNER	LERSVQRRYP	YLLPLNAIQI	900
ELRRYRAGE	DTFLVSKTIQ	VTMNGLATGL	RTSG			934

SEQ ID NO: 5 moltype = DNA length = 5719
 FEATURE Location/Qualifiers
 source 1..5719
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 5

tgccgcaagc	actcaggggc	caagggctgc	taaaggaagc	ggaacacgta	gaaagccagt	60
ccgcagaaac	gggtgctgacc	ccggatgaat	gtcagctact	gggctatctg	gacaagggaa	120
aacgcaagcg	caaagagaaa	gcaggtagct	tgcagtggcg	ttacatggcg	atagctagac	180
tggcggttt	tatggacagc	aagcgaaccg	gaattgccag	ctggggcgcc	ctctggtaag	240
gttgggaagc	cctgcaaaag	aaactggatg	gctttcttgc	cgccaaggat	ctgatggcgc	300
aggggatcaa	gatctgatca	agagacagga	tgaggatcgt	ttcgcatgat	tgaacaagat	360
ggattgcacg	caggtttctcc	ggcgccttgg	gtggagagcg	tattcggcta	tgactgggca	420
caacagacaa	tcggctgctc	tgatgccgcc	gtgttccggc	tgtcagcgca	ggggcgcccc	480
gttctttttg	tcaagaccga	cctgtccggc	gccctgaatg	aactccaaga	cgaggcagcg	540
cggctatcgt	ggctggccac	gacgggcgtt	ccttgccgag	ctgtgctcga	cgttgtcact	600
gaagcgggaa	gggactggct	gctattgggc	gaagtgcggg	ggcaggatct	cctgtcatct	660
caacttgctc	ctgcgagaaa	agtatccatc	atggctgatg	caatgcggcg	gctgcatacg	720
cttgatccgg	ctacctgccc	attcgaccac	caagcgaaac	atcgcatcga	gcgagcacgt	780
actcggatgg	aagccggtct	tgtcgatcag	gatgatctgg	acgaagagca	tcaggggctc	840
gcgcagccg	aactgttcgc	caggctcaag	gcgcggatgc	cgacggcgca	ggatctcgtc	900
gtgaccatg	cggatgctgc	cttgccgaat	atcatgggtg	aaaatggccg	cttttctgga	960
ttcatcgact	gtggccggct	gggtgtggcg	gaccgctatc	aggacatagc	gttggctacc	1020
cgtgatattg	ctgaagagct	tgccggcgaa	tgggctgacc	gcttctcgt	gctttacggc	1080
atcccgctc	cggattcgca	gcgcctcgcc	ttctatcgcc	ttcttgacga	gttctcttga	1140
cgcggaactc	gggttctcgt	agaggatcga	tcctttttta	cccatcacat	atacctgccg	1200
ttcactatta	tttagtga	tgagatatta	tgatatttct	tgaattgtga	ttaaaaaggc	1260
aaactttatg	ccatgcaaca	gaaactataa	aaaatacaga	gaatgaaaaa	aaacagatag	1320
atttttttag	tcctttaggcc	cgtagtctgc	aaatcctttt	atgattttct	atcaaacaaa	1380
agaggaaaaa	gtaccagctc	caatccaaac	gagagtctaa	tagaatgagg	tcgaaaaagta	1440
aatcgccg	gtttgttact	gataaaagcag	gcaagacctc	aaatgtgtta	agggcacaagt	1500
gtatactttg	gcgtcacccc	ttacatattt	taggtccttt	tttatgttgc	gtaactaact	1560
tgccatcttc	aaacaggagg	gctggaagaa	gcagaccgct	aacacagtac	ataaaaaagg	1620
agacatgaac	gatgaacatc	aaaaagtttg	caaaaacaagc	aacagtatta	acctttacta	1680
ccgcactgct	ggcaggaggc	gcaactcaag	cgtttgcgaa	agaaacgaac	caaaagccat	1740
ataaggaaa	atacggctat	tcccatatta	cacgccatga	tatgctgcaa	atccctgaac	1800
agcaaaaaaa	tgaataatat	caagtttctg	aatttgattc	gtccacaatt	aaaaatatct	1860
cttctgcaaa	aggcctggac	gtttgggaca	gctggccatt	acaaaacgct	gacggcactg	1920
tcgcaaaacta	tcacggctat	catatcgctc	ttgcattagc	cggagatcct	aaaaatcgcg	1980
atgacacatc	gatttacatg	ttctatcaaa	aagtcggcga	aacttctatt	gacagctgga	2040
aaaacgctgg	ccgcgtcttt	aaagacagcg	acaaattcga	tgcaaatgat	tctatcctaa	2100
aagacccaaa	acaagaatgc	tcagggttcag	ccacattttac	atctgacgga	aaaatccggt	2160
tattctacac	tgattttctc	ggtaaacatt	acggcaaaac	aacactgaca	actgcacaag	2220
ttacgctatc	agcatcagac	agctctttga	acatcaacgg	tgtagaggat	tataaatcaa	2280
tccttgacgg	tgacggaaaa	acgtatcaaa	atgtacagca	gttcatcgat	gaaggcaact	2340
acagctcagg	cgacaaccat	acgctgagag	atcctcacta	cgtagaagat	aaaggccaca	2400
aatacttagt	atttgaagca	aacactggaa	ctgaagatgg	ctaccaaggc	gaagaatctt	2460
tatttaacaa	agcatactat	ggcaaaaagca	catcattctt	ccgtcaagaa	agtcaaaaac	2520
ttctgcaaa	cgataaaaaa	cgacaggctg	agttagcaaa	cgccgctctc	gggatgattg	2580
agctaaacga	tgatttacaca	ctgaaaaaag	tgatgaaacc	gctgattgca	tctaacacag	2640
taacagatga	aattgaacgc	gcgaacgctc	ttaaaatgaa	cggcaaatgg	tacctgttca	2700
ctgactcccg	cggatcaaaa	atgacgattg	acggcattac	gtctaacgat	attttacatg	2760
ttggttatgt	ttctaattct	tttaactggc	catacaagcc	gctgaacaaa	actggccttg	2820
tgttaaaaat	ggatcttgat	cctaacgatg	taacctttac	ttactcacac	ttcgctgtac	2880
ctcaagcgaa	aggaacaat	gtcgtgatta	caagctatat	gacaaacaga	ggattctacg	2940
cagacaaaca	atcaacgctt	gcgcgagct	tcctgctgaa	catcaaaagg	aagaaaaacat	3000
ctgttgctca	agacagcatc	cttgaacaag	gacaattaac	agttaaacaa	taaaaacgca	3060
aaagaaaaat	ccgatgggta	ccgagcgaaa	tgaccgacca	agcgacgccc	aaactgccat	3120
cacgagattt	cgattccacc	gccgccttct	atgaaagggt	gggcttcgga	atcgttttcc	3180
gggacgcctc	cgcgagcgtg	ctcatagtc	acgacgccc	tgattttgta	gccctggccg	3240
acggccagca	cgtaggccga	caggctcatg	ccggccgccc	ccgccttttc	ctcaatcgct	3300
cttcgttcgt	ctggaaggca	gtacaccttg	ataggtgggc	tgcccttctc	ggttggtctg	3360
gtttcatcag	ccatccgctt	gccctcatct	gttacgcgg	cggtagccgg	ccagcctcgc	3420
agagcaggat	tcccggttgag	caccgccagg	tgcaataaag	ggacagtga	gaaggaaacac	3480
ccgctcgcgg	gtgggcctac	ttcacctatc	ctgcccggct	gacgccgttg	gatacaccaa	3540
ggaaagtcta	caggaacccct	ttggcaaaat	cctgtatata	gtgcgaaaaa	ggatggatat	3600
accgaaaaaa	tcgctataat	gacccggaag	cagggttatg	cagcggaaaa	gcgctgcttc	3660
cctgctgttt	tgtggaatat	ctaccgactg	gaaacaggca	aatgcaggaa	attactgaac	3720
tgaggggaca	ggcgagagac	gatgcaaaag	agctcctgaa	aatctcgata	actcaaaaaa	3780
tacgcccggc	agtgatctta	tttcattatg	gtgaaagtgt	gaacctctta	cgtgccgatc	3840
aacgtctcat	tttcgcca	agttggccca	gggcttcccg	gtatcaacag	ggacaccagg	3900
atattattat	tctcggaagt	gatcttccgt	cacaggatatt	tattcggcgc	aaagtgcgtc	3960

-continued

```

gggtgatgct gccaaacttac tgatttagtg tatgatgggtg tttttgaggt gctccagtg 4020
cttctgtttc tatcagctcc tgaaaatctc gataaactcaa aaaatacggc cggtagtgat 4080
cttattttcat tatggtgaaa gttggaacct cttacgtgcc gatcaacgtc tcatttttcgc 4140
caaaagttgg cccagggtctt cccggtatca acagggacac caggatttat ttattctgcg 4200
aagtgatctt ccgtcacagg tatttattcg gcgcaaatg cgctgggtga tgetgccaac 4260
ttactgattt agtgatgat ggtgtttttg aggtgctcca gtggcttctg tttctatcag 4320
ggctggatga tcctccagcg cggggatctc atgctggagt tcttcgcccc ccccaaaagg 4380
atctagggtga agatcctttt cgataatctc atgacccaaa tcccttaacg tgagttttctg 4440
ttccactgag cgctcagacc cgtagaaaag atcaaaaggat cttcttgaga tccctttttt 4500
ctgctcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggg ggtttgtttg 4560
ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgagata 4620
ccaaatactg ttcttctagt gtagecgtag ttaggccacc acttcaagaa ctctgtagca 4680
ccgctacat accctgctct gctaactctg ttaccagtg ctgctgccag tggcgataag 4740
tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc 4800
tgaaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga 4860
taacctacgc gtgagctatg agaaagcgcc acgcttcccg aaggagaaaa ggcggacagg 4920
tatccggtaa gcgcgagggt cggacacgga gagcgacga gggagcttc agggggaaac 4980
gcctggatcc tttatagctc tgcgggttt cgcacacct ctaactgagc tcgatttttg 5040
tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg 5100
ttcctggcct tttgctggcc ttttgcctac atgttcttcc ctgctgtatc cctgattct 5160
gtggataacc gtattaccgc ctttgagtga gctgataccg ctgcgcgcag ccgaacgacc 5220
gagcgacgcg agtcagtgag cagggaagcg gaagagcgcc caatacgcaa accgcctctc 5280
cccgcgctt gcgcgattca ttaatgcagc tggcacgaca gggttccgca ctggaaagcg 5340
ggcagtgagc gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta 5400
cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca 5460
ggaaacagct atgacatgat tacgccaagc ttgcatgcct gcaggtcgac tctagaggat 5520
ccccgggtac cgagctcgaa ttcaactggc gtcgttttac aacgtctgta ctgggaaaac 5580
cctggcgtaa ccaacttaa tcgccttgca gcacatcccc ctttcgccag ctggcgtaat 5640
agcgaagagg cccgcacgga tcgcccttcc caacagttgc gcagcctgaa tggcgaaatgg 5700
cgataagcta gcttcacgc 5719

```

```

SEQ ID NO: 6      moltype = DNA length = 20
FEATURE          Location/Qualifiers
source           1..20
                 mol_type = other DNA
                 organism = synthetic construct

```

```

SEQUENCE: 6
ctctgctcgc tcaactggtct 20

```

```

SEQ ID NO: 7      moltype = DNA length = 21
FEATURE          Location/Qualifiers
source           1..21
                 mol_type = other DNA
                 organism = synthetic construct

```

```

SEQUENCE: 7
tactcgctgt gtcgtagegg g 21

```

1. A phosphoenolpyruvate carboxylase variant in which one or more of the amino acids at positions 472 and 673 in the amino acid sequence of SEQ ID NO: 4 is/are substituted with other amino acid(s).

2. The phosphoenolpyruvate carboxylase variant of claim 1, which consists of the amino acid sequence of SEQ ID NO: 2 in which proline at position 472 in the amino acid sequence of SEQ ID NO: 4 is substituted with serine and glycine at position 673 is substituted with aspartic acid.

3. A polynucleotide encoding the variant of claim 1.

4. A transformant comprising the variant of claim 1.

5. The transformant of claim 4, which is a *Corynebacterium* sp. microorganism.

6. The transformant of claim 4, which has ability to produce 5'-inosinic acid.

7. A method for producing 5'-inosinic acid, comprising steps of:

culturing the transformant of claim 4 in a medium; and recovering 5'-inosinic acid from the transformant or the medium in which the transformant has been cultured.

8. A transformant comprising the polynucleotide of claim 3.

* * * * *